Sat, Dec 20, 2014, 12:22 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

oldfolks95610 13 posts  |  Last Activity: Dec 13, 2014 2:50 PM Member since: Dec 27, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Today's price action was a scam

    by o0o0o77 Dec 12, 2014 10:22 PM
    oldfolks95610 oldfolks95610 Dec 13, 2014 2:50 PM Flag

    I kept thinking the stock price was subject to error on Friday. Just terribly odd, not enough volume for anyone to make millions maybe a few G's

  • Reply to

    JUNO IPO another like KITE maybe better

    by oldfolks95610 Dec 9, 2014 9:41 PM
    oldfolks95610 oldfolks95610 Dec 9, 2014 10:03 PM Flag

    SAN FRANCISCO (TheStreet) -- Treatment with re-engineered immune cells designed to kill leukemia has led to complete remissions in more than 90% of a small group of children and young adults with an aggressive form of the disease enrolled in an ongoing, early-stage study.

    More than two-thirds of the patients remain cancer free six months following treatment and 75% of patients are still alive, said researchers from the University of Pennsylvania and Novartis (NVS) , speaking during a media briefing Saturday at the American Society of Hematology (ASH) annual meeting taking place here.

    This new form of cancer immunotherapy, which scientists refer to as CAR-T for the receptor added to killer T cells in the lab, promises to radically change the way certain blood cancers are treated. CAR-T therapies are also generating tremendous commercial and investor interest. The UPenn-Novartis joint venture is competing with Juno Therapeutics, a red-hot private company expected to price a $150 million initial public offering early next year.

    Other CAR-T companies include Kite Therapeutics (KITE) and a joint venture between Celgene (CELG) and Bluebird Bio (BLUE) .

    The study updated today enrolled 39 children and young adults with relapsed, treatment-resistant acute lymphocytic leukemia (ALL). After the experimental UPenn-Novartis treatment known as CTL019 was given, 36 of 39 patients, or 92%, went into complete remission, meaning there was no evidence of disease in their bodies. Six months after receiving CTL019, 70% of patients remain cancer free, and only five patients ha

  • Seattle-based Juno plans to raise $153 million in its initial public offering, selling 9.3 million shares at a price of 15 to 18. At the midpoint of the proposed range, Juno would have a market value of roughly $1.5 billion. That would make it the largest biotech IPO of 2014 by market cap, at the time of its IPO, according to IPO ETF manager Renaissance Capital.

    Meanwhile, Kite Pharma (NASDAQ:KITE), which is also developing immunotherapies for the treatment of cancer, rose 17% to close at 51.56 on the stock market today. Kite Pharma raised $128 million in its June 20 IPO, offering 7.5 million shares at 17. But with its run-up, Kite's market cap now is flying just under $2 billion

    If we have a good day this one may explode. It certainly got a lot of attention from the venture capitalist.
    OLD

  • Reply to

    Awesome!!!! BLUE Skies

    by oldfolks95610 Dec 8, 2014 11:12 PM
    oldfolks95610 oldfolks95610 Dec 9, 2014 2:57 PM Flag

    This is amazing, all my engineering stocks following BLUE. Sold the KITE at 50 and it went up another 3. Too good almost now a little anxious. KITE is on the cusp of an offering and I will get back in on that if t happens. CLDN, QURE,SGMO,ISIS,SRPT and I guess some I don't have.
    Old

  • oldfolks95610 by oldfolks95610 Dec 8, 2014 11:12 PM Flag

    ISIS and BLUE both up 4 dollars and change today from my basket of Genetic engineered bios. I only have 200 of each but Blue up 20.00 after hours on trial results!! Nice wish I had more but my basket has about 2k shares in several engineered stocks and most are up well so I can't complain. KITE,QURE,CLDN,SGMO and others.
    Merry Christmas, Old

  • oldfolks95610 by oldfolks95610 Dec 1, 2014 12:37 AM Flag

    An unmet need for knees: Biotech Histogenics sets terms for $60 million IPO

    11/14/14

    Histogenics, a biotech developing a therapy for repairing knee cartilage using its tissue repair platform, announced terms for its IPO on Friday. The Waltham, MA-based company plans to raise $60 million by offering 4.3 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Histogenics would command a fully diluted market value of $158 million.

    The deal is 58% covered, as insiders plan to purchase $20 million worth of shares on the offering while August 2013 biotech Intrexon (XON) has indicated it would invest $15 million.

    Founded in 2000, Histogenics plans to list on the NASDAQ under the symbol HSGX. Cowen & Company, Needham and Canaccord Genuity are the joint bookrunners on the deal. It is expected to price during the week of December 1, 2014. Less

    Just noticed this and was thinking maybe stepping on some ones platform.

  • oldfolks95610 by oldfolks95610 Nov 7, 2014 2:32 PM Flag

    New highs daily, hard to hold for the long term.
    Old

  • oldfolks95610 oldfolks95610 Oct 29, 2014 9:32 PM Flag

    The photos in the SA story are very telling. For PVCT

  • M Plaut
    Long only, special situations, dividend investing, value
    Profile| Send Message| Follow (27 followers)
    The Product Development Story Of Provectus Biopharmaceuticals
    Jul. 28, 2014 1:47 PM ET | About: Provectus Biopharmaceuticals, Inc. (PVCT)
    Disclosure: The author is long PVCT. (More...)
    Summary

    Provectus Biopharmaceuticals is developing a product with a very compelling story.
    Its premier product is PV-10, used in cancerous tumors, notably melanoma.
    PV-10 destroys tumors by homing in on their acidic environment and exploding the cancerous cells.
    PV-10 also primes the immune system and causes destruction of tumors that were never injected.
    When Provectus Biopharmaceuticals Inc. (NYSEMKT:PVCT) announced at the end of May that the FDA had denied it Breakthrough Therapy Designation (BTD)
    it caused a sharp drop in the stock price. The extreme move in the stock market obscured the significant and steady progress forward that the company has been making in the development of its premiere product: PV-10 (Rose Bengal) as a treatment for various types of cancer. PVCT is not just a stock that can be shorted and traded, pumped and dumped, but it is also a biotech company that is developing a product that has a rich and interesting story that is worth telling.

    The way traders have beaten down the stock, it may seem as if there is nothing behind the stock symbol. However the company has an advisory board composed of 2 senior executives of Pfizer (NYSE:PFE), a senior executive of Sanofi (NYSE:SNY), a senior executive of Bayer (OTCPK:BAYRY), a senior executive with Boehringer Ingelheim (a private $17billion drug company) and a senior executive of the Livestrong anticancer organization. These are busy business people who would not give their names and their time to a company unless they were sure that it has a promising technology

    This complete story on SA is worth a read. A very different drug. Maybe worth the gamble for a couple x's.
    Old and confused

  • oldfolks95610 oldfolks95610 Oct 4, 2014 9:35 PM Flag

    It took a decade for her idea to be ready for primetime, but now it seems that her decision to drop out was undoubtedly a good call. Last year, Walgreen Co. announced that it would be installing Theranos Wellness Centers in pharmacies across the country, with locations already up and running in Phoenix and Palo Alto, California. And Holmes has raised $400 million in venture capital for Theranos, which is now valued at $9 billion (Holmes owns 50%).

    The other two 30-year-olds on Forbes' List, Facebook founder Mark Zuckerberg and his former roommate and Facebook CEO Dustin Moskovitz, also have access to a wealth of information about people — but their data is less likely to directly save a life.

    Read more: http://www.businessinsider.com/theranos-founder-elizabeth-holmes-is-a-billionaire-2014-9#ixzz3FEKgZ6iu
    I think she might be single Nah
    Olddy

  • The next time you get a blood test, you might not have to go to the doctor and watch vials of blood fill up as the precious fluid is drawn from your arm.

    No more wondering to yourself, "Ah, how much more can they take before I pass out?"

    Instead you might be able to walk into a Walgreens pharmacy for a reportedly painless fingerprick that will draw just a tiny drop of blood, thanks to Elizabeth Holmes, 30, the youngest woman and third-youngest billionaire on Forbes' newly released annual ranking of the 400 richest Americans.

    Revolutionizing the blood test is a golden idea.

    Because of new testing methods developed by Holmes' startup Theranos, that lone drop can now yield a ton of information.

    The company can run hundreds of tests on a drop of blood far more quickly than could be done with whole vials in the past — and it costs a lot less.

    A Billion-Dollar Idea

    Holmes dropped out of Stanford at 19 to found what would become Theranos after deciding that her tuition money could be better put to use by transforming healthcare

  • oldfolks95610 by oldfolks95610 Sep 29, 2014 10:28 PM Flag

    Released good data from trial today to expand usage of already approved drug and dumped 7 %.
    "That said, we do have this from Needham and Co." "This morning Seattle Genetics reported positive top-line data from the pivotal AETHERA trial of ADCETRIS. The trial met its primary endpoint with a highly significant and meaningful increase in progression free survival (PFS). Investors, however, appear to be reacting negatively to the disclosure that a pre-planned interim overall survival (OS) analysis was not statistically significant, despite the fact that these data are not yet mature. We are buyers of SGEN shares on weakness

    today as we believe concerns over the interim OS data are overblown." Less
    May catch a good trade over the next couple days. I made good money on her but sold too soon at 25-28
    last year.
    Old

  • oldfolks95610 by oldfolks95610 Sep 25, 2014 1:03 PM Flag

    Good to get a bit of help for the fires. Market could be better, not trading much but trying to hold some stocks.
    Maybe better to put money in tin cans ehh. Go A's and Gigantes still a little hope.
    Old and wet

SGEN
32.89-0.15(-0.45%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.